doi: 10.3389/fimmu.2022.997578 Received 19 July 2022 Accepted 24 November 2022 Published 08 December 2022 Volume 13 - 2022 Edited by Jorg Hermann Fritz, McGill University, Canada Reviewed by Cristian Loretelli, University of Milan, Italy
Share your experimental results or join a short interview to earn up to $1,000 in product credits or other rewards
Harris L, Hamilton S, Azevedo LB, Olajide J, De Brn C, Waller G et al (2018) Intermittent fasting interventions for overweight and obesity
The confirmed cancer concern with GLP-1 agonists involves thyroid C-cell tumors, based on rodent studies showing medullary thyroid carcinoma at high drug exposures
Study Identifies 3 Strategies to Minimize Muscle Loss from GLP-1 Weight Loss Drugs. Medical News Today, 14 Apr